We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biotechnology firm Abivax has lifted the curtain on new Phase 2a data for its HIV therapy ABX464, showing that the drug was able to reduce levels of the virus’ DNA in blood and rectal tissue.